Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, explores the results of a subgroup analysis of the GREEN study (NCT01905943), evaluating obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).